Inhibition of phospholipase A2 as a therapeutic target

被引:81
|
作者
Yedgar, S [1 ]
Lichtenberg, D
Schnitzer, E
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel
关键词
phospholipase A(2); secretory PLA(2); eicosanoid; inflammatory process; anti-inflammatory drug; inhibition of PLA(2); cell-impermeable PLA(2) inhibitor;
D O I
10.1016/S1388-1981(00)00120-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hydrolysis of cell membrane phospholipids by phospholipase A(2) (PLA(2)) leads to the production of numerous lipid mediators of diverse pathological conditions, mainly inflammatory diseases. These include lysophospholipids and their derivatives, and arachidonic acid and its derivatives (the eicosanoids). Both these groups of mediators are produced predominantly by the secretory PLA(2)s (sPLA(2)s) which hydrolyze the phospholipids of the cell surface membrane. Protection of cell membrane from these 'inflammatory enzymes' can therefore be used for the treatment of inflammatory processes. A prototype of cell-impermeable PLA(2) inhibitors, which protect the cell membrane from different sPLA(2)s without affecting vital phospholipid metabolism, is presented and discussed in the present review. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:182 / 187
页数:6
相关论文
共 50 条
  • [31] PHOSPHOLIPASE A2 AND COMPETITIVE INHIBITION OF PROCOAGULANT PHOSPHOLIPIDS
    BOFFA, MC
    BOFFA, GA
    THROMBOSIS ET DIATHESIS HAEMORRHAGICA, 1975, 34 (03): : 899 - 899
  • [32] Noncompetitive inhibition of phospholipase A2 activity by magnesium
    Petroianu, G
    Helfrich, U
    Maleck, W
    Bergler, W
    Rufer, R
    MAGNESIUM-BULLETIN, 1998, 20 (03): : 69 - 72
  • [33] Anthracycline-induced phospholipase A2 inhibition
    Swift, Luther
    McHowat, Jane
    Sarvazyan, Narine
    CARDIOVASCULAR TOXICOLOGY, 2007, 7 (02) : 86 - 91
  • [34] Lipoprotein-associated phospholipase A2 (Lp-PLA2): Relevant biomarker and therapeutic target?
    Bonnefont-Rousselot, Dominique
    ANNALES PHARMACEUTIQUES FRANCAISES, 2025, 83 (01): : 45 - 57
  • [35] Cytosolic phospholipase A2 (cPLA2) as a therapeutic target in basal-like breast cancer
    Moestue, S. A.
    Grinde, M. T.
    Marangoni, E.
    Serlie, T.
    Engebraten, O.
    Maelandsmo, G. M.
    Johansen, B.
    Bathen, T. F.
    CANCER RESEARCH, 2013, 73
  • [36] Lipoprotein-associated phospholipase A2:: a novel marker of cardiovascular risk and potential therapeutic target
    Macphee, C
    Benson, GM
    Shi, Y
    Zalewski, A
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (06) : 671 - 679
  • [37] Role of lipoprotein-associated phospholipase A2 in atherosclerosis -: Biology, epidemiology, and possible therapeutic target
    Zalewski, A
    Macphee, C
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) : 923 - 931
  • [38] Mammalian phospholipase A2:: Phospholipase A2 receptor
    Hanasaki, K
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (08) : 1165 - 1167
  • [39] Antisense inhibition of phospholipase A2: A new approach for already tested therapeutic targets for the treatment of sepsis
    Touqui, Lhousseine
    CRITICAL CARE MEDICINE, 2012, 40 (07) : 2250 - 2251
  • [40] Lipoprotein-associated phospholipase A2:: a new biomarker for cardiovascular risk assessment and potential therapeutic target
    Carlquist, John F.
    Muhlestein, Joseph B.
    Anderson, Jeffrey L.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007, 7 (05) : 511 - 517